Safety profile of an oral nasal decongestant/antihistamine combination in pediatrics: a real-world experience/ Perfil de segurança de uma combinação de descongestionante nasal e anti-histamínico em crianças: uma experiência de mundo real

Authors

  • Mauro Luis de Mello Ferreira
  • Sergio Graff
  • Gabriela Pacheco de Oliveira
  • Karen Sacoman Barbosa
  • Anna Paula Bispo Lacerda
  • Stevin Zung

DOI:

https://doi.org/10.34119/bjhrv4n6-103

Keywords:

pharmacovigilance, phenylephrine, brompheniramine, safety .

Abstract

ObjectiveThe objective of this work is to characterize the safety profile of phenylephrine and brompheniramine in pediatric patients through the evaluation of post-marketing pharmacovigilance data. Method:Adverse events and situations grouped as medication errors, occurring in patients aged from zero to 12 years exposed to Decongex Plus received by the pharmacovigilance department of Aché Laboratórios Farmacêuticos during the period from 2/1/2014 to 9/30/2019 were included in this study. The events were grouped according to the age of the patients and classificated regard seriousness and expectedness. The data found were compared with other studies of the same gender and with international database.Results:A total of 1,391 adverse events occurred in patients aged between 0-12 years were included. The results showed a total incidence of adverse events of 0.0035% (rare according to local legislation). The majority (62.68%) occurred in the age group of 2 to 6 years of age. In this age group, 97.82% of the adverse events were considered non-serious, the majority being somnolence, and only 2.18% of the events were considered serious. In children over 7 years of age (8.62% of the total), it was also found that most adverse events (94.16%) were non-serious. The age group under two years of age totaled 28.68% of the adverse events received, with 98% being considered non-serious (main event was also somnolence) and 67% being medication errors. Conclusions:The study points to a favorable safety profile of phenylephrine and brompheniramine in pediatric patients. Randomized, controlled clinical studies are warranted to confirm these findings.

References

Natali RT. et al. Hospital admissions due to respiratory diseases in children and adolescents of São Paulo city, 2000-2004. Rev Paul Pediatr 2011;29(4):584-90.

Passali D. et al. The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018 Jan;8(1):e7.

Sakano E et al. IV Consenso Brasileiro sobre Rinite - atualização em rinite alérgica. 2018 Jan; 84 (1).

Suleimani YM, Walker MJA. Allergic rhinitis and its pharmacology. Pharmacology & Therapeutics 114 (2007) 233–260.

Sur DK, Scandale S. Treatment of Allergic Rhinitis. Am Fam Physician. 2010;81(12):1440-1446.

Green JL. et al. Safety Profile of Cough and Cold Medication Use in Pediatrics. Pediatrics. 2017;139(6).

Organização Pan-Americana da Saúde (OPAS). A importância da Farmacovigilância: Monitorização da segurança dos medicamentos [internet]. Brasília: World Health Organization; 2005. 47 p. [Accessed on Jul. 01, 2020]. Available at: http://portal.anvisa.gov.br/documents/33868/399730/A+importancia+da+Farmacovigilancia+-+Monitorizacao+da+seguranca+dos+medicamentos/3c042e31-c594-4f7d-b41d-1665e9064bd0

Agência Nacional de Vigilância Sanitária (Anvisa). Collegiate Board Resolution No. 406, of July 22, 2020. Brazil.

WHO - World Health Organization. International drug monitoring. The role of National Centres. Technical Report Series, Genebra, n. 498, 1972. Received on March

, 2005. Accepted on November 18, 2005.

Agência Nacional de Vigilância Sanitária (Anvisa). Collegiate Board Resolution No. 47, of September 8, 2009. Brazil.

Smith SM, Schoeder K, Fahey T. Over‐the‐counter (OTC) medications for acute cough in children and adults in community settings. 2014. Cochrane Systematic Review CD001831.

Funding

This work was supported by Aché Laboratórios Farmacêuticos S.A.

Downloads

Published

2021-11-14

How to Cite

FERREIRA, M. L. de M.; GRAFF, S.; OLIVEIRA, G. P. de; BARBOSA, K. S.; LACERDA, A. P. B.; ZUNG, S. Safety profile of an oral nasal decongestant/antihistamine combination in pediatrics: a real-world experience/ Perfil de segurança de uma combinação de descongestionante nasal e anti-histamínico em crianças: uma experiência de mundo real. Brazilian Journal of Health Review, [S. l.], v. 4, n. 6, p. 24889–24905, 2021. DOI: 10.34119/bjhrv4n6-103. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/39537. Acesso em: 29 mar. 2024.

Issue

Section

Original Papers